Characteristics of patients at baseline
| Placebo (n = 34) | Ciclosporin (n = 38) | |
|---|---|---|
| Women, No (%) | 19 (56) | 27 (71) |
| Age (years), mean (SD) | 47.1 (10.8) | 46.8 (11.5) |
| Race (%): | ||
| Caucasian | 31 (91) | 35 (92) |
| Asian | 2 (6) | 3 (8) |
| Other | 1 (3) | 0 (0) |
| Disease duration (months), mean (SD) | 42.4 (41.9) | 40.8 (33.0) |
| Dactylitis, No (%) | 7 (21) | 7 (18) |
| Nail dystrophy, No (%) | 22 (65) | 22 (58) |
| Enthesitis, No (%) | 6 (18) | 9 (24) |
| Uveitis, No (%) | 1 (3) | 0 (0) |
| HLA-B27, No (%) | 9 (26) | 6 (16) |
| DR4, No (%) | 8 (24) | 11 (29) |
| Concomitant treatment at baseline: | ||
| NSAIDs, No (%) | 26 (76) | 30 (79) |
| Prednisolone (⩽10 mg/day), No (%) | 0 (0) | 2 (5) |
| Tender joint index, mean (SD) | 44.3 (38.2) | 35.4 (34.8) |
| Tender joint count, mean (SD) | 28.3 (19.2) | 22.6 (15.9) |
| Swollen joint count, mean (SD) | 11.7 (8.6) | 11.7 (9.7) |
| CRP (mg/l), mean (SD) | 15.4 (13.3) | 17.4 (14.5) |
| PASI score, mean (SD) | 2.2 (2.7) | 2 (2.3) |
| Larsen score, mean (SD) | 36 (28.7) | 33 (27) |